Full text

Turn on search term navigation

© 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Aims

Sodium glucose co‐transporter 2 inhibitors have diuretic effects in both patients with glycosuria and with natriuresis. We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) in patients with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF).

Methods and results

This study was a post‐hoc analysis of the MUSCAT‐HF trial (UMIN000018395), a multicentre, prospective, open‐label, randomized controlled trial that assessed the effect of 12 weeks of luseogliflozin (2.5 mg, once daily, n = 83) as compared with voglibose (0.2 mg, three times daily, n = 82) on the reduction in brain natriuretic peptide (BNP) in patients with type 2 diabetes and HFpEF. The analysis compared the change in ePV calculated by the Straus formula from baseline to Weeks 4, 12, and 24, using a mixed‐effects model for repeated measures. We also estimated the association between changes in ePV and changes in other clinical parameters, including BNP levels. Luseogliflozin significantly reduced ePV as compared to voglibose at Week 4 {adjusted mean group‐difference −6.43% [95% confidence interval (CI): −9.11 to −3.74]}, at Week 12 [−8.73% (95%CI: −11.40 to −6.05)], and at Week 24 [−11.02% (95%CI: −13.71 to −8.33)]. The effect of luseogliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in ePV at Week 12 was significantly associated with log‐transformed BNP (r = 0.197, P = 0.015) and left atrial volume index (r = 0.283, P = 0.019).

Conclusions

Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes and HFpEF.

Details

Title
Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
Author
Nakashima, Mitsutaka 1 ; Miyoshi, Toru 1 ; Ejiri, Kentaro 2 ; Kihara, Hajime 3 ; Hata, Yoshiki 4 ; Nagano, Toshihiko 5 ; Takaishi, Atsushi 6 ; Toda, Hironobu 7 ; Nanba, Seiji 8 ; Nakamura, Yoichi 9 ; Akagi, Satoshi 10 ; Sakuragi, Satoru 11 ; Minagawa, Taro 12 ; Kawai, Yusuke 13 ; Nishii, Nobuhiro 14 ; Fuke, Soichiro 15 ; Yoshikawa, Masaki 16 ; Nakamura, Kazufumi 1 ; Ito, Hiroshi 1 

 Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 
 Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, Department of Internal Medicine, Tamano City Hospital, Okayama, Japan 
 Department of Internal Medicine, Kihara Cardiovascular Clinic, Asahikawa, Japan 
 Department of Cardiology, Minamino Cardiovascular Hospital, Hachioji, Japan 
 Department of Internal Medicine, Iwasa Hospital, Gifu, Japan 
 Department of Cardiology, Mitoyo General Hospital, Kanonji, Japan 
 Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, Department of Internal Medicine, Okayama East Neurosurgery Hospital, Okayama, Japan 
 Department of Cardiology, Okayama Rosai Hospital, Okayama, Japan 
 Department of Cardiovascular Medicine, Specified Clinic of Soyokaze CardioVascular Medicine and Diabetes Care, Matsuyama, Japan 
10  Department of Internal Medicine, Akaiwa Medical Association Hospital, Okayama, Japan 
11  Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan 
12  Department of Internal Medicine, Minagawa Cardiovascular Clinic, Gifu, Japan 
13  Department of Cardiovascular Medicine, Okayama City Hospital, Okayama, Japan 
14  Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, Department of Internal Medicine, Yoshinaga Hospital, Bizen, Japan 
15  Department of Cardiovascular Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan 
16  Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan 
Pages
712-720
Section
Original Articles
Publication year
2022
Publication date
Feb 1, 2022
Publisher
John Wiley & Sons, Inc.
e-ISSN
20555822
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2622462985
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.